TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05380245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole 200 mg x 2 Tablets
Description: Name of medication of Reference Formulation: Tablets Voriconazole Vfend®, 200 mg by Pfizer, Inc. (USA), (Batch No: 00005505; Mfg. date 09/2016).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole 200 mg x 2 Tablets
Description: Name of medication of Reference Formulation: Tablets Voriconazole Vfend®, 200 mg by Pfizer, Inc. (USA), (Batch No: 00005505; Mfg. date 09/2016).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg x 1Tablets
Description: Name of medication of Intervention Formulation: Tablet Klaricid, 500 mg by Abbott, Lab Pvt. Ltd. (Karachi, Pakistan), Batch No: 81573XU; Mfg. date 10/2017.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg x 1Tablets
Description: Name of medication of Intervention Formulation: Tablet Klaricid, 500 mg by Abbott, Lab Pvt. Ltd. (Karachi, Pakistan), Batch No: 81573XU; Mfg. date 10/2017.
Study: NCT00584584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAX576

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04630678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Therapy
Description: Virtual reality games were applied to participants for 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: Joint and muscle mobilization, strengthening, and stretching exercises by neurodevelopmental treatment principles were applied to participants for 30 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Physiotherapy
Description: Joint and muscle mobilization, strengthening, and stretching exercises by neurodevelopmental treatment principles were applied to participants for 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activity Training
Description: Unilateral, bilateral, and bimanual activity training that supported manual skills for 30 minutes.
Study: NCT03263455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping group
Description: The tape in the KT group will be applied with paper-off tension, which means applying the tape directly to the skin as it comes off the paper backing (approximately with 15% to 25% of available tension). KinesioTape will be applied over the SCM dystonic muscle by means of 2 I-strips: the first strip will be placed on the medial (sternal) head and the second will be applied on the lateral (clavicular) head of the SCM muscle. KinesioTape was applied from the mastoid bone to the clavicle (rostrocaudal direction) with the SCM placed in a position of maximum stretching.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Taping
Description: Patients in the ST group, smaller I-strips of KinesioTape will be used and they will be applied, with no tension and without stretching the muscles, perpendicularly to the muscle belly (starting from the middle and progressing to each side) over the same dystonic muscles as in the experimental group. Although the specific therapeutic elements of KinesioTaping (ie, longitudinal stretch, start and ending point tape application) will be removed
Study: NCT02779491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-a-day fruit and vegetable mobile phone application
Description: 5-a-day fruit and vegetable mobile phone application

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-a-day fruit and vegetable mobile phone application
Description: 5-a-day fruit and vegetable mobile phone application
Study: NCT02599532

Intervention type: DRUG
Group type: OTHER
Intervention: apixaban
Description: Study subjects will be given a single-dose of apixaban 10 mg.

Intervention type: DRUG
Group type: OTHER
Intervention: apixaban
Description: Study subjects will be given a single-dose of apixaban 10 mg.
Study: NCT02945436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substance Use Brief Intervention
Description: SUBI is a counseling intervention based on Motivational Interviewing techniques that focuses on the substance use and sexual health risks of participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substance Use Brief Intervention
Description: SUBI is a counseling intervention based on Motivational Interviewing techniques that focuses on the substance use and sexual health risks of participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Substance Use Brief Intervention
Description: SUBI is a counseling intervention based on Motivational Interviewing techniques that focuses on the substance use and sexual health risks of participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Standard of care is Counseling Testing and Referral (CTR). CTR is a standardized service in which counselors provide HIV testing, risk-related counseling and appropriate referrals (medical, social, prevention, and partner services) to clients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: Standard of care is Counseling Testing and Referral (CTR). CTR is a standardized service in which counselors provide HIV testing, risk-related counseling and appropriate referrals (medical, social, prevention, and partner services) to clients.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC)
Description: Standard of care is Counseling Testing and Referral (CTR). CTR is a standardized service in which counselors provide HIV testing, risk-related counseling and appropriate referrals (medical, social, prevention, and partner services) to clients.
Study: NCT00026247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pain therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Study: NCT04149444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: Oral medication
Study: NCT04608071

Intervention type: PROCEDURE
Intervention: A modified method for blind bedside placement of post-pyloric feeding tube.
Description: Modified post-pyloric feeding tube bedside catheterization as an optimized bedside blind post-pyloric tube placement, significantly shortened the time for passing pylorus without causing any severe adverse reactions.

Intervention type: PROCEDURE
Intervention: A modified method for blind bedside placement of post-pyloric feeding tube.
Description: Modified post-pyloric feeding tube bedside catheterization as an optimized bedside blind post-pyloric tube placement, significantly shortened the time for passing pylorus without causing any severe adverse reactions.

Intervention type: PROCEDURE
Intervention: A modified method for blind bedside placement of post-pyloric feeding tube.
Description: Modified post-pyloric feeding tube bedside catheterization as an optimized bedside blind post-pyloric tube placement, significantly shortened the time for passing pylorus without causing any severe adverse reactions.
Study: NCT01626066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM015
Description: LUM015 assigned dose given once by IV push
Study: NCT03469115

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum blood
Description: Serum blood test for laboratory analysis to determine level of alpha defensin

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Serum blood
Description: Serum blood test for laboratory analysis to determine level of alpha defensin
Study: NCT00324922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trimethoprim-sulfamethoxazole
Description: trimethoprim/sulfamethoxazole 320/1600 mg po bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin
Description: 1g iv bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vancomycin
Description: 1g iv bid
Study: NCT00902577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMISO
Description: FMISO PET scans

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: Undergo MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET
Description: Undergo FMISO PET scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRS
Study: NCT03173417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IM19 CAR-T
Description: T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine and cyclophosphamide
Description: Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days
Study: NCT02306889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: 130mg Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANTARA® (fenofibrate)
Description: 130mg Capsules
Study: NCT01139996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: An oral loading dose of Clonidine 0.3 mg and placement of Clonidine Transdermal system at a dose of 0.3-mg/day (Catapres TTS-3), with patch overlay, followed by a final dose of Clonidine 0.3mg after 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final tablet
Study: NCT04232007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: closed-loop system for vasopressor administration
Description: closed-loop system for vasopressor administration
Study: NCT03102502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EECP
Description: Enhanced external counterpulsation (EECP) is a technique for assisting the circulation by decreasing the afterload of the left ventricle and augmenting the diastolic pressure externally by applying a negative pressure to the lower extremities during cardiac systole. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. EECP enhances the aortic diastolic blood flow and coronary perfusion, leading to increased arterial wall shear stress in a pulsatile manner.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical therapy
Description: Guideline- driven standard medical treatment including statins,antiplatelet drugs（aspirin or Clopidogrel ）, anti-ischemic drugs （Nitroglycerin）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical therapy
Description: Guideline- driven standard medical treatment including statins,antiplatelet drugs（aspirin or Clopidogrel ）, anti-ischemic drugs （Nitroglycerin）
Study: NCT02597309

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Canagliflozin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canagliflozin
Study: NCT03918265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: On refractory autoimmune cytopenia patients, tacrolimus was tried. Dosage: 1mg bid and tacrolimus trough targets were 5-10 ng/ml throughout the study
Study: NCT03322293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminolevulinic Acid Topical 20% Topical Solution
Description: PDT involves the topical application of aminolevulinic acid (ALA), or one of its derivatives, as a photosensitizing agent. Subjects will receive ALA in all treatment arms (A, B, and C).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid Topical 20% Topical Solution
Description: PDT involves the topical application of aminolevulinic acid (ALA), or one of its derivatives, as a photosensitizing agent. Subjects will receive ALA in all treatment arms (A, B, and C).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid Topical 20% Topical Solution
Description: PDT involves the topical application of aminolevulinic acid (ALA), or one of its derivatives, as a photosensitizing agent. Subjects will receive ALA in all treatment arms (A, B, and C).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BLU-U blue light phototherapy illuminator
Description: Depending on the treatment arm, subjects will either receive BLU-U exposure or not. Treatment arms A and B have BLU-U exposure and treatment arm C does not.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLU-U blue light phototherapy illuminator
Description: Depending on the treatment arm, subjects will either receive BLU-U exposure or not. Treatment arms A and B have BLU-U exposure and treatment arm C does not.
Study: NCT02815306

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyaxial brace
Description: The Polyaxial brace were made by a technician trained by the China National Disabled Persons Federation. For all patients, gypsum models were prepared first, and then braces were fabricated according to the models. The detailed technique was fully in accordance with the Ponseti method.
Study: NCT01586234

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DSAEK with graft shaping and smoothing
Description: 1. A 5mm incision will be made in the sclera (white portion) of the eye, approximately 1mm from the edge of the cornea~2. The tissue on the underside of the cornea (endothelium) will be scraped away~3. The graft from the donor cornea (previously smoothed with a laser) will be inserted through the incision and placed against the endothelium of the host cornea.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard DSAEK
Description: 1. A 5mm incision will be made in the sclera (white portion) of the eye, approximately 1mm from the edge of the cornea~2. The tissue on the underside of the cornea (endothelium) will be scraped away~3. The graft from the donor cornea will be inserted through the incision and placed against the endothelium of the host cornea.
Study: NCT02525016

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Study: NCT02899611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: ICV Valproate is a dilution of the commercially available Epilim product, which is a sterile intravenous (IV) formulation of Sodium Valproate.
Study: NCT02938364

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Earplugs
Description: Plastic earplugs on both ears

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Sea Bands put on the wrists of the participant to apply pressure on P6 points

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non pressure bands put on the wrists of the participant
Study: NCT00956085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Open label memantine titrated in 5mg increments weekly to target dose of 10mg po bid for up to 6 weeks. Memantine was continued to 12 weeks in those with treatment response,13 either previous response to ketamine (≥ 35% Y-BOCS reduction 1 week after IV ketamine) or current response to memantine (≥ 35% Y-BOCS reduction from pre- to post-6 weeks of memantine).
Study: NCT01800045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitolisant
Description: 1 capsule in the morning before breakfast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule in the morning before breakfast
Study: NCT03936088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention -- Headspace mindfulness application
Description: Patients will be provided with a pre-paid 12-week subscription to the mindfulness application, and provided an in-person demonstration on how to use it, and the subscription license code will be recorded for the purposes of tracking use after the conclusion of the study. The intervention group will be asked to use the mindfulness app 10 minutes per day/5 days per week. To standardize Pack usage across all participants, users will be asked to complete the Headspace Essentials, Pain Management, and Physical Health Session Packs.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control -- My Water Balance application
Description: My Water Balance calculates an individual's recommended daily water requirements and assists users in tracking their daily fluid intake. The control group will be asked to log their water intake for the duration of the study, with requested use of 5 days per week to create an equal control. This application is free to download and use. There are options for in-app purchases and application upgrades, though users will be advised against doing so. Information logged in the application may be stored on a third party server; however, no application data will be extracted by the study team. Application use will be reported via weekly surveys, alone.
Study: NCT01290718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: 900mg/m2 bid po on days 1-14 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab [Herceptin]
Description: 8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg iv every 3 weeks
Study: NCT04237948

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: cerebellar tDCS consists in the application of a low intensity (1-2 mA) steady current through a surface scalp electrode over the cerebellum

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Hospitalized patients will undergo a 60 minutes physical treatment improving gait and postural instability for four weeks of time

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical therapy
Description: Hospitalized patients will undergo a 60 minutes physical treatment improving gait and postural instability for four weeks of time
Study: NCT05954052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutathione
Description: Giving supplement orally
Study: NCT02533700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEOP/IVE/GDP chemotherapy regimen
Description: CEOP:~Cyclophosphamide 750mg/m2, ivgtt D1 Epirubucin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5~IVE:~Ifosfamide 2000mg/m2,ivgtt D1-D3 Epirubucin 70mg/m2, ivgtt D1 Etoposide 100mg/m2, ivgtt D1-D3~GDP:~Gemcitabine 1g/m2,ivgtt D1,D8 Cis-platinum 25mg/m2, ivgtt D1-D3 Dexamethasone 40mg, ivgtt D1-D4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEOP chemotherapy regimen for 6 cycles
Description: CEOP:~Cyclophosphamide 750mg/m2, ivgtt D1 Epirubucin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2 （max 100mg）,PO,D1-D5 every 21 days for total 6 courses
Study: NCT06519916

Intervention type: BEHAVIORAL
Intervention: Assessment of mental performance
Description: There was no intervention, the mental performance was assessed

Intervention type: BEHAVIORAL
Intervention: Assessment of mental performance
Description: There was no intervention, the mental performance was assessed
Study: NCT02087774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6 minutes activity
Description: Group added 6 minutes of physical activity daily during school day.
Study: NCT03073772

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer-based cognitive training
Description: A total of 36 training sessions, approximately 20 minutes long each. Five different tasks were used in training all tapping different aspects of cognitive control such as updating, shifting, visuo-spatial working memory and episodic memory binding.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical fitness training
Description: A total of 36 training sessions, approximately 40 minutes long each, with physical fitness training performed as group indoor cycling. The participants were instructed to attain a load of approximately 65-80% of their maximum heart rate.
Study: NCT02306876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562 3mg BID
Description: PF-06412562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06412562 15mg BID
Description: PF-06412562
Study: NCT03150836

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: In all arms of the study, participants will receive 5 fractions of radiation. The radiation dose will either be 6.6 Gy for a total dose of 33 Gy, or 6.0 Gy for a total dose of 30 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: In all arms of the study, participants will receive 5 fractions of radiation. The radiation dose will either be 6.6 Gy for a total dose of 33 Gy, or 6.0 Gy for a total dose of 30 Gy.
Study: NCT02306876

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02704312

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy by Prone and decubitus
Description: Dosimetric comparison of doses in target volumes and organs at risk
Study: NCT01635660

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: Tracheal Intubation with the assigned video laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: Tracheal Intubation with the assigned video laryngoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: Tracheal Intubation with the assigned video laryngoscope
Study: NCT01991353

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: With PRP
Description: Following meniscal repair, PRFM will be delivered arthroscopically into the tear site using a portal skid, arthroscopic canula and arthroscopic atraumatic tissue grasper into the interface of the repair site.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Without PRP
Description: Standard of care meniscal repair without augmentation.
Study: NCT02456727

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group/Community Acupuncture
Description: Acupuncture treatment in a group setting.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Individual Acupuncture
Description: Acupuncture treatment in an individual setting.
Study: NCT02652169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRF mixed with amikacin and teicoplanin
Description: PRF, mixed with amikacin and teicoplanin is applied to the chronic ulcer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRF mixed with PHMB plus Macrogolol
Description: PRF, mixed with Lavasorb is applied to the chronic ulcer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRF plus normal saline
Description: PRF as a monosubstance plus sodium chloride 0.9% is applied to the chronic ulcer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Silver gauze
Description: Acticoat 7 silver wound dressing is applied to the chronic ulcer